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Abstract 
Aristolochic acid (AA) is the causative agent of urothelial tumours associated with aristolochic acid 
nephropathy. These tumours contain TP53 mutations and over-express TP53. We compared 
transcriptional and translational responses of two isogenic HCT116 cell lines, one expressing TP53 
(p53-WT) and the other with this gene knocked out (p53-null), to treatment with aristolochic acid I 
(AAI) (50−100 µM) for 6−48 h. Modulation of 118 genes was observed in p53-WT cells and 123 
genes in p53-null cells. Some genes, including INSIG1, EGR1, CAV1, LCN2 and CCNG1, were 
differentially expressed in the two cell lines. CDKN1A was selectively up-regulated in p53-WT 
cells, leading to accumulation of TP53 and CDKN1A. Apoptotic signalling, measured by caspase-3 
and -7 activity, was TP53-dependent. Both cell types accumulated in S phase, suggesting that AAI-
DNA adducts interfere with DNA replication, independently of TP53 status. The oncogene MYC, 
frequently over-expressed in urothelial tumours, was up-regulated by AAI, whereas FOS was down-
regulated. Observed modulation of genes involved in endocytosis, e.g. RAB5A, may be relevant to 
the known inhibition of receptor-mediated endocytosis, an early sign of AA-mediated proximal 
tubule injury. AAI-DNA adduct formation was significantly greater in p53-WT cells than in p53-
null cells. Collectively, phenotypic anchoring of the AAI-induced expression profiles to DNA 
adduct formation, cell-cycle parameters, TP53 expression and apoptosis identified several genes 
linked to these biological outcomes, some of which are TP53-dependent. These results strengthen 
the importance of TP53 in AA-induced cancer, and indicate that other alterations, e.g. to MYC 
oncogenic pathways, may also contribute. 
 
 
Keywords: Aristolochic acid, urothelial cancer, TP53, gene expression, apoptosis, microarray  
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Introduction 
Aristolochic acid nephropathy (AAN) is a unique type of renal disease that predisposes patients to a 
high risk of urothelial cancer (Vanherweghem et al., 1993; Nortier et al., 2000; Lord et al., 2001). 
The observed nephropathy has been traced to the ingestion of herbal medicinal remedies that have 
included Aristolochia species containing aristolochic acid (AA) (Arlt et al., 2002). Natural health 
products containing AA are often sold as traditional Chinese medicines for weight loss, improving 
the immune system or alleviating gastrointestinal symptoms (Gold and Slone, 2003; Wu et al., 
2007). AA is a strong rodent carcinogen, being among the most potent 2% of known carcinogens 
(Gold and Slone, 2003). Herbal remedies containing Aristolochia species have been classified as 
carcinogenic to humans (Group 1) by the International Agency for Research on Cancer (IARC) 
(IARC, 2002). 
AA is a mixture of two structurally similar nitro-phenanthrene carboxylic acids, aristolochic 
acid I (AAI) and aristolochic acid II (AAII). There is clear evidence that AA is a mutagen forming 
covalent DNA adducts (Arlt et al., 2002). We have detected specific AA-DNA adducts in various 
tissues of AA-treated rats (Stiborova et al., 1994) and in urothelial tissue of AAN patients 
(Schmeiser et al., 1996; Nortier et al., 2000). The most abundant DNA adduct detected was the 
adenosine adduct of AAI, 7-(deoxyadenosin-N6-yl)aristolactam I (dA-AAI) (Schmeiser et al., 1996; 
Nortier et al., 2000; Lord et al., 2001). Although AA-DNA adducts are also found in tissues outside 
the urinary tract (Arlt et al., 2004), specific DNA damage due to AA in urothelial cells and cell-
specific alterations of certain physiological processes (Lebeau et al., 2001; Lebeau et al., 2005) may 
explain the observed high incidence of urothelial tumours induced by AA.  
 The TP53 tumour suppressor functions as a key player in determining cell fate after DNA 
damage and disabling its function by mutations in its coding sequence leads to the development of 
tumours (Hussain et al., 2000). More than 50% of all human tumours contain a TP53 mutation 
(Petitjean et al., 2007). Transcriptional modulation of TP53-target genes leads to the regulation of 
downstream processes, primarily cell-cycle arrest, apoptosis and DNA repair that protect the cell 
from DNA damage and transformation. AAN urothelial atypia have been associated with the over-
expression of TP53, suggesting that TP53 is mutated in AAN-associated tumours (Cosyns et al., 
1999; Arlt et al., 2001b). Interestingly, in the one AAN patient available so far for analysis we 
found an AT→TA transversion mutation in TP53 in urothelial tumour cells (Lord et al., 2004). 
AT→TA transversions are typical mutations observed in the H-ras oncogene of tumours in rodents 
treated with AA and are consistent with AA-DNA adduct formation primarily at adenine residues 
(Schmeiser et al., 1990; Arlt et al., 2000). These data indicate a possible molecular mechanism 
whereby AA causes urothelial cancer.  
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 Toxicogenomics can provide the means to define relationships between toxicological end-
points and gene expression patterns, predict toxic responses, and identify mechanisms of toxicity of 
environmental agents such as AA (Chen et al., 2006; Guo et al., 2006; Stemmer et al., 2007). In 
order to examine the role of TP53 in cellular responses to AA we have used cDNA microarrays to 
analyse transcriptional responses in a pair of human colorectal cell lines (HCT116) that differ in 
TP53 status (i.e. wild-type [p53-WT] or knock-out [p53-null]) after exposure to the main 
component AAI and we have investigated the influence of duration of exposure and concentration 
of AAI on the observed responses. In addition, other biological parameters including DNA adduct 
formation, cell-cycle, apoptosis and protein expression were compared between the two cell lines. 
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Materials and Methods  
Aristolochic acid I 
A commercial natural plant extract AA (Roth, Germany) was subjected to three sequential 
recrystallizations from boiling dimethylformamide-water. The orange crystals thus dried under 
vacuum yielded around 98% pure AAI as determined by reversed-phase HPLC. The analysis of the 
AAI by high-field 1H-NMR and mass spectrometry was fully consistent with its structure. AAI was 
converted to its sodium salt by neutralization with aqueous sodium hydroxide. The solution was 
thoroughly mixed and taken to dryness under reduced pressure, yielding the sodium salt of AAI 
quantitatively as a water-soluble deep-red amorphous powder. 
 
Cell culture  
Two isogenic HCT116 human colorectal carcinoma cell lines (Bunz et al., 1998), one expressing 
wild-type TP53 (p53-WT) and the other with complete knockout of TP53 (p53-null), were kindly 
provided by B. Vogelstein, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 
Cells were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with Glutamax™ I, 1000 
mg/L D-glucose and sodium pyruvate (Invitrogen, UK) and supplemented with 10% foetal bovine 
serum and 100 U penicillin/ml and 100 µg streptomycin/ml (Sigma Aldrich, UK). Cells were grown 
as adherent monolayers and sub-culturing was performed every 72 h when cells were 80% 
confluent and incubated in a humidified 5% CO2 atmosphere at 37°C (Hockley et al., 2008). For 
treatment, cells were grown for 48 h until 70% confluent and then the appropriate concentrations of 
AAI (as sodium salt) dissolved in water were added. Water only was added to control cultures. 
Cells were harvested by trypsinisation and then washed with PBS. 
 
Cell viability and DNA adduct analysis 
Cells (2.25×106) were seeded in T75 flasks in a total volume of 15 ml and after 48 h exposed to 0, 
1, 10, 50 or 100 µM AAI. All incubations were performed in duplicate. Cell viability (% control) 
was determined using a Vi-Cell Cell Viability Analyzer (Beckman Coulter, UK) after exposure to 
AAI for 6, 24 or 48 h. Cells were spun down, and from each pellet DNA was isolated by a standard 
phenol chloroform extraction method (Arlt et al., 2001b). DNA was quantified 
spectrophotometrically and DNA adducts were determined for each DNA sample (4 µg) using the 
nuclease P1 enrichment version of the 32P-postlabelling method as described previously (Mei et al., 
2006; Phillips and Arlt, 2007). Chromatographic conditions for thin-layer chromatography (TLC) 
on polyethyleneimine-cellulose (PEI-cellulose) were: D1, 1.0 M sodium phosphate, pH 6.0; D3, 3.5 
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M lithium formate, 8.5 M urea, pH 4.0; and D4, 0.8 M lithium chloride, 0.5 M Tris-HCl, 8.5 M 
urea, pH 9.0. TLC sheets were scanned by using a Packard Instant Imager (Dowers Grove, IL, 
USA), and DNA adduct levels (RAL, relative adduct labelling) were calculated from the adduct 
cpm, the specific activity of [γ-32P]ATP and the amount of DNA (pmol of DNA-P) used. Results 
were expressed as DNA adducts/108 nucleotides. Enzymatic preparations of AA-DNA adduct 
reference compounds were performed as described (Arlt et al., 2001a). For DNA adduct formation, 
3-Nitrobenzanthrone (3-NBA; 5 µM) was used as a positive control (Arlt et al., 2005; Arlt et al., 
2007a). 
 
Microarray and gene expression analysis 
Cells (2.25×106) were seeded in T75 flasks in a total volume of 15 ml and after 48 h exposed to 0, 
50 or 100 µM AAI. All incubations were performed in triplicate. After exposure to AAI for 6, 24 or 
48 h cell pellets were collected and total RNA extracted using the Qiagen RNeasy Mini Kit protocol 
(RNeasy Mini Handbook, Qiagen, UK). After addition of lysis buffer (RLT, Qiagen) samples were 
homogenised using QIAshredders (Qiagen). RNA was quantified spectrophotometrically, and 
integrity was determined using a 2100 Bioanalyzer (Agilent Technologies, UK) so that only RNA 
samples that had an rRNA 28S/18S ratio greater than 1.5 were used for microarray analysis. Total 
RNA (4 µg) was reverse transcribed into cDNA and fluorescently labelled with Cy3 or Cy5 mono-
reactive dyes (Amersham Biosciences, UK) using the Invitrogen Indirect cDNA Labelling Kit 
protocol (Invitrogen) as described (Hockley et al., 2006; Hockley et al., 2007; Hockley et al., 2008). 
 Gene expression analysis was performed using the Cancer Research UK DNA Microarray 
Facility (CRUKDMF) Human 22K Genome-Wide Array v1.0.0. The full probe list for this array 
can be found at the CRUKDMF website (http://www.icr.ac.uk/array/array.html). The arrays were 
gridded onto Type 7* silanised slides (GE Healthcare, UK) followed and hybridisation, washing 
and scanning of the slides were performed as described (Hockley et al., 2006; Hockley et al., 2007). 
RNA from exposed cells and time-matched vehicle-treated control cells hybridised against each 
other for each dose and time-point from each triplicate biological experiment. 
 Image analysis using GenePix Pro v-5.1 software (Axon Instruments) and data 
normalisation within GeneSpring v-7.2 (Agilent Technologies, UK) were performed as described 
(Hockley et al., 2008). Briefly, after Lowess normalisation and filtering out of unreliable data, 
triplicate biological replicates were averaged to identify genes with significantly (P < 0.05) altered 
expression by at least 1.4-fold. Log2 transformed data were used for any correlation (hierarchical 
clustering, principal components analysis [PCA]) and statistical algorithms (1-Way ANOVA) 
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performed within GeneSpring. The web-accessible program DAVID (Database for Annotation, 
Visualization, and Integrated Discovery) was used for functional gene annotation (Dennis et al., 
2003). Significant genes were uploaded into Expression Analysis Systematic Explorer (EASE 
version 2.0) for functional analysis (Hosack et al., 2003). Biological processes significantly over-
represented within the gene expression alterations had an EASE score assigned by EASE of less 
than 0.05. 
 The gene expression data discussed in this publication have been deposited in the National 
Center for Biotechnology (NCBI) Gene Expression Omnibus database 
(http://www.ncbi.nlm.nih.gov/geo/) and are accessible through GEO Series accession number 
GSE10359. 
 
Real-time quantitative PCR (RTqPCR) 
Two-step reverse transcription-PCR was used to generate cDNA for relative quantitation analysis 
using real-time fluorescent PCR on an ABI PRISM 7900HT Sequence Detection System (Applied 
Biosystems, UK) performed as previously described (Hockley et al., 2006; Hockley et al., 2007; 
Hockley et al., 2008). To detect the modulated expression of selected target genes 20x Assays-On-
DemandTM gene expression primers and probes (Applied Biosystems) were used (ALDH1A3-
Hs00167476_m1, CCNG1-Hs00171112_m1, HIST1H4B-Hs00374342_s1, SCD-Hs00748952_s1, 
MYC-Hs00153408_m1, FOS-Hs00170630_m1, RHOB-Hs00269660_s1, NR1D1-
Hs00253876_m1, CAV1-Hs00184697_m1, CDKN1A-Hs00355782_m1, and CYP1A1-
Hs00153120_m1). Relative gene expression was calculated using the comparative threshold cycle 
(CT) method.  
 
Western blot analysis 
For Western blot analysis 3×105 cells were seeded per well of a six-well plate in a total volume of 2 
ml medium and exposed after 48 h to 0, 10, 50 or 100 µM AAI for 6, 24 or 48 h. Cell pellets were 
then collected and lysis and immunoblotting were performed as previously described (Hockley et 
al., 2006; Hockley et al., 2007; Hockley et al., 2008). Monoclonal antibody against TP53 (Ab-6) 
was purchased from Calbiochem (Darmstadt, Germany) and diluted 1:5000. Detection of CDKN1A 
(p21) was by monoclonal antibody purchased from Santa Cruz Biotechnology (CA, USA), diluted 
1:500. For detection of CYP1A1 we used a polyclonal antibody in a 1:500 dilution (Affinity 
BioReagents, Golden, CO, USA). Monoclonal antibody to detect GAPDH (6C5) was purchased 
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from Chemicon Europe (Hampshire, UK), diluted 1:5000 and used as a loading control. 3-NBA (5 
µM) was used as a positive control. 
 
Apoptosis assay 
Cells were seeded (1.5×104 per well) in a 96-well plate in 0.1 ml medium and after 48 h exposed to 
0, 50 or 100 µM AAI. All incubations were performed in triplicate. After exposure to AAI for 6, 24 
or 48 h the activity of caspase-3 and -7 was measured using the Caspase-Glo assay kit (Promega, 
Southampton, UK) according to the manufacturer’s instructions. Luminescent signal was detected 
using a Microtiter Plate Luminometer (DYNEX Technologies, UK). Luminescence was 
proportional to the amount of caspase activity present. 3-NBA (5 µM) was used as a positive 
control. 
 
Flow cytometry 
For cell cycle analysis 7.5×105 cells were seeded in T25 flasks in a total volume of 5 ml and after 
48 h exposed to 0 or 100 µM AAI. All incubations were performed in duplicate. After exposure to 
AAI for 6, 24 or 48 h cells were fixed in ethanol as previously described (Hockley et al., 2006). 
Fixed cells were stored at –20°C overnight, centrifuged (640 g, 3 min, 4°C) and after removing the 
supernatant 1 ml DAPI staining solution (Partec, Münster, Germany) was added. The samples were 
kept at room temperature for 4 h in the dark and analysed for DNA content using a PAS flow 
cytometer and FlowMax software (Partec, Münster, Germany) for evaluation of cell cycle 
distribution.  
  
Induction of oxidative damage to DNA  
DNA strand breaks and formamidopyrimidine-DNA glycosylase (Fpg)-sensitive sites were 
determined by the alkaline unwinding technique in combination with bacterial Fpg. Cells (7.5×105 
cells) were seeded in T25 flasks in a total volume of 5 ml and after 48 h exposed to 0 or 100 µM 
AAI. All incubations were performed in duplicate. After exposure to AAI for 6, 24 or 48 h cells 
were prepared as described (Schwerdtle et al., 2003). The Fpg protein was a generous gift of Dr. S. 
Boiteux (Commisariat Energie Atomique, Fontenay-aux-Roses, France) and used at a concentration 
of 1 µg/ml. For the detection of DNA strand breaks, Fpg was omitted. Unwinding of DNA, 
neutralisation and separation of single- and double-stranded DNA were performed as described 
previously (Hartwig et al., 1996). The DNA content of both fractions was determined by adding 
Hochest 33258 and measuring the fluorescence with a spectrophotofluorometer (SPECTRA Fluor, 
 9
Tecan, Switzerland) at an excitation wavelength of 360 nm and an emission wavelength of 455 nm. 
The number of DNA strand breaks and Fpg-sensitive sites were calculated as described (Hartwig et 
al., 1996). Hydrogen peroxide (H2O2; 100 µM for 5 min on ice) was used as a positive control. 
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Results 
HCT116 p53-WT and p53-null cell viability 
HCT116 p53-WT and p53-null cells were exposed to up to 100 µM AAI for up to 48 h to examine 
the effect of loss of TP53 function on cell viability (Figure 1). Short exposure time (6 h) and low 
AAI concentrations (1 or 10 µM) had little or no effect on cell viability in both cell lines. However, 
differences in viability between p53-WT and p53-null cells were observed after exposure to 50 or 
100 µM AAI. A reduction in viable cells of up to 50% was observed in p53-WT cells after 24 and 
48 h (Figure 1A). In p53-null cells no effect on cell viability was found after 24 h and at 50 µM, but 
exposure to 100 µM AAI resulted in up to a 30% reduction of viable cells at 48 h (Figure 1B). 
 
DNA adduct analysis 
DNA adduct formation in HCT116 p53-WT and p53-null cells exposed to up to 100 µM AAI (0, 
10-100 µM) for up to 48 h was analysed using 32P-postlabelling (Figure 2). In p53-WT cells the 
adduct pattern was qualitatively similar to that found in AAN patients, consisting of two major 
adduct spots (spots 1 and 2) and one minor (spot 3) (Schmeiser et al., 1996; Bieler et al., 1997; 
Nortier et al., 2000). As shown in Figure 2A (inset), the two major adducts were identified as 
reported previously (Schmeiser et al., 1996; Bieler et al., 1997) as 7-(deoxyadenosin-N6-
yl)aristolactam I (spot 1; dA-AAI) and 7-deoxyguanosin-N2-yl)aristolactam I (spot 2; dG-AAI), and 
the minor adduct as 7-(deoxyadenosin-N6-yl)aristolactam II (spot 3; dA-AAII). In p53-null cells 
only exposure to 100 µM AAI for 48 h resulted in DNA adduct formation (Figure 2B; inset), dA-
AAI being the only adduct detected. No DNA adducts were detected in controls (data not shown). 
Quantitative analysis obtained by 32P-postlabelling revealed a dose-dependent formation of AA-
DNA adducts in p53-WT cells (Figure 2A). Total AA-DNA adduct levels after 48 h ranged from 
0.7 to 133 adducts per 108 nucleotides. In contrast, DNA adduct levels in p53-null cells were 3.5 
adducts per 108 nucleotides (100 µM AAI; 48 h), being ~40-fold lower than those levels in p53-WT 
cells (Figure 2B). DNA adduct formation in p53-WT and p53-null cells was significantly different 
(P<0.05; Welch’s two-sample t-test with adjustment for multiple corrections using Benjamin-
Hocberg). Moreover, a multiple regression model fitted to the p53-WT DNA adduct data 
demonstrated a statistically significant linear trend for both time (P=0.031) and concentration (50 
and 100 µM; P<0.0001). For 3-NBA, which was used as positive control, DNA adduct levels were 
similar in both pairs of cells (Figure 2).   
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Gene expression analysis 
To determine differences in basal gene expression between the HCT116 p53-WT and p53-null cells, 
both cell lines were harvested 24 h after seeding and directly compared on the microarrays. 
GeneSpring software identified 32 (16 up-regulated, 16 down-regulated) cDNA clones that were 
significantly (P<0.05) modulated by at least 1.4-fold in p53-null relative to p53-WT cells (see 
Supporting Table 1 and 2). Genes up-regulated in the p53-null cells are likely candidates of 
transcriptional repression by functional TP53. Most notably, included in this list are 4 genes (K-
ALPHA-1, H2-ALPHA, TUBA-1 and TUBA3) that encode cytoskeletal proteins. This suggests that 
TP53 plays an important role in maintaining the expression of cell structural genes. The list of 
genes down-regulated in cells lacking TP53 confirms the genotypic status of these cells with 
transcripts of TP53 and its transcriptional target CDKN1A significantly reduced relative to WT cells.  
 A principle aim of this study was to identify gene expression changes induced by AAI 
related to genotoxicity in relation to the TP53 status at levels without severe cell toxicity. Therefore, 
AAI concentrations of 50 and 100 µM and exposure times of up to 48 h were chosen for the 
microarray experiments; these conditions resulted in DNA adduct formation, and induction of TP53 
and CDKN1A proteins (see below; compare Figure 5) but not a severe reduction in cell viability. 
As shown in Figure 3A, filtering of Lowess normalised gene expression data at 50 and 100 µM at 6, 
24 or 48 h in GeneSpring software identified 133 (82 up-regulated, 51 down-regulated) and 138 (67 
up-regulated, 71 down-regulated) cDNA clones that were modulated by at least 1.4-fold and that 
had a significant t-test P value (<0.05) in at least one sample of the p53-WT and p53-null cells, 
respectively (see Supporting Tables 3 and 4). Sixty one genes were modulated in the same direction 
(39 up-regulated, 22 down-regulated) by AAI in both cell lines suggesting that these genes are 
modulated by TP53-independent mechanisms. AAI had very subtle effects on gene expression in 
both cell lines with few genes exceeding a 2-fold change in expression. Hierarchical clustering of 
the gene expression profiles revealed that the gene expression profiles were relatively similar after 
exposure to 50 µM AAI and an exposure period of 6 h, independently of TP53 status (Figure 4A). 
However, gene expression profiles at 100 µM AAI clustered according to longer exposure times (24 
and 48 h) and TP53 status. PCA confirmed that, overall, AAI-induced gene expression profiles 
were more dependent on the concentration tested and the longer exposure time, than on the TP53 
status of the cells (Figure 4B). Thus, for functional gene expression analysis we focused only on 
gene changes observed at 100 µM AAI for 24 and 48 h.  
 As shown in Figure 3B, 118 genes in total (77 up-regulated, 41 down-regulated) were 
significantly modulated by at least 1.4-fold in p53-WT and 123 genes (58 up-regulated, 65 down-
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regulated) in p53-null cells (see Supporting Tables 5 and 6), confirming that most of the gene 
changes found occurred only at the highest concentration tested (100 µM) and after longer exposure 
times (24 and 48 h; compare Figure 3A). The program DAVID (Dennis et al., 2003) was used for 
functional gene annotation. The most up-regulated genes in p53-WT cells were KLF10 and EGR1. 
The early growth response 1 (EGR1) gene is a transcription factor that acts both as a tumour 
suppressor and as a tumour promoter (Krones-Herzig et al., 2005). In p53-null cells NR1D1 was the 
most up-regulated gene, which is linked to the mammalian circadian rhythm (Preitner et al., 2002). 
SCD which encodes for stearoyl-CoA desaturase involved in fatty acid biosynthesis was the most 
down-regulated gene in both cell lines. We found that a number of histone genes (HIST1H1C, 
HIST1H2AC, HIST1H3D, HIST1H3E, HIST1H4B, and HIST1H4C) were strongly up-regulated both 
in p53-WT and p53-null cells. We also found gene expression changes in oncogenes, such as MYC 
and RHOB, which were both up-regulated only in p53-null cells, and FOS, which was down-
regulated in both cell lines. Two changed genes were associated with endocytosis (NECAP1 and 
RAB5A) which may be important as AA was previously shown to inhibit receptor-mediated 
endocytosis (Lebeau et al., 2001; Lebeau et al., 2005). A number of gene changes in p53-WT 
(CDKN1A, CSE1L, CTNNAL1, NFKBIA, PPP2CA, STRN3, and UBE2V2) and p53-null cells (MYC, 
CCNG1, RPA2, and YARS) were linked with apoptosis and/or cell cycle regulation. One gene, 
XRCC4, was linked to DNA repair and was up-regulated only in p53-WT cells. 
 An overlap of 56 genes (37 up-regulated, 19 down-regulated) was found in p53-WT and 
p53-null cells after AAI exposure suggesting that these genes are modulated independently from 
TP53. In GeneSpring, 1-Way ANOVA was performed on the list of all genes modulated by AAI in 
the two cell lines (185 genes) to identify genes that are the most differently expressed between p53-
WT and p53-null cells. These TP53-discriminating genes with their associated expression ratios can 
be seen in Table 1. EGR1, INSIG1 and NR1D1 are involved in regulation of transcription; CAV1, 
CCNG1, INSIG1, LCN2 and PLP2 are involved in cell growth and/or maintenance. Encouragingly, 
this list includes TP53-regulated genes such as CCNG1 which is involved in cell cycle regulation 
(Ohtsuka et al., 2004). CCNG1 and CAV1 were down-regulated only in p53-null cells. Although 
EGR1 was up-regulated in both cell lines, it was up-regulated much more strongly in p53-WT cells. 
Two genes that are involved in metabolism, CPM and ALDH1A3, were up-regulated only in p53-
WT cells.  
 To determine whether any biological themes exist within the expression data of the HCT116 
cells exposed to AAI, EASE analysis was performed to identify biological processes that are 
significantly over-represented (EASE score <0.05) in the gene lists when compared to their total 
representation on the microarray (Table 2). Over-represented themes among the up-regulated genes 
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in both cell lines included regulation of transcription (e.g. RNA splicing/processing/metabolism), 
replication (e.g. nucleic acid metabolism and chromatin assembly/disassembly) and metabolism (e.g. 
amino acid and carbohydrate metabolism, protein biosynthesis). No over-represented themes were 
found among the down-regulated genes in p53-WT cells. In p53-null cells this list included 
biosynthesis (e.g. protein and macromolecule biosynthesis), metabolism (e.g. protein metabolism) 
and secretion. 
 
RTqPCR 
RTqPCR, a more sensitive and specific measure of gene expression, was carried out in HCT116 
p53-WT and p53-null cells exposed to 0 or 100 µM AAI for 48 h to validate a number of interesting 
expression changes and to validate the microarray data. Ten genes (ALDH1A3, CCNG1, HIST1H4B, 
SCD, MYC, FOS, ROHB, NR1D1, CAV1, and CDKN1A) were selected to be measured by RTqPCR.  
In the majority of cases the RTqPCR data confirmed the microarray data (Table 3). Agreement 
between the microarray and RTqPCR was 80% which is consistent with a previous study using the 
same microarray (Hockley et al., 2007). CDKN1A was strongly up-regulated in p53-WT cells using 
RTqPCR confirming results obtained on the protein level (see below; compare Figure 5B). 
Although MYC was up-regulated significantly on the microarray in p53-WT cells, its modulation 
was slightly below the cut-off of 1.4 (data not shown). However, using RTqPCR MYC was clearly 
overexpressed in p53-WT cells after AAI exposure, indicating that RTqPCR is a more sensitive 
measure of gene expression in this case. RTqPCR was also used to measure the expression of 
CYP1A1, known to be involved in the metabolic activation of AA (Stiborova et al., 2005; Stiborova 
et al., 2008), but not present on the microarray. Increased expression of CYP1A1was found in both 
cell lines, although the expression level was lower in the p53-null cells (Table 3). 
 
Western blot analysis 
TP53 levels in HCT116 p53-WT and p53-null cells were assessed by Western blot analysis in order 
to confirm its accumulation in response to the AAI concentrations used. Protein levels were 
analysed in both cell lines exposed to up to 100 µM AAI (0, 10-100 µM) for up to 48 h (Figure 5). 
As expected, TP53 was not detectable in p53-null cells (Figure 5A). In p53-WT cells no increase in 
TP53 in comparison to controls was observed after 6 (data not shown) and 24 h; induction of TP53 
was observed only after exposure to 50 or 100 µM AAI for 48 h. A similar expression pattern was 
found for CDKN1A accumulation (Figure 5B). Clear CDKN1A induction was observed in p53-WT 
cells, but only after exposure to 50 or 100 µM AAI for 48 h. Basal levels of CDKN1A observed in 
 14
p53-null cells at 48 h remained unchanged by AAI-treatment. For 3-NBA, which was used as 
positive control, induction of TP53 and CDKN1A was observed in p53-WT cells only (data not 
shown). Since AAI is known to be metabolically activated by CYP1A1 (Stiborova et al., 2005; 
Stiborova et al., 2008), we investigated CYP1A1 expression in both cell lines. No difference in the 
basal or induction levels of CYP1A1 between p53-WT and p53-null cells was observed (data not 
shown). 
 
Apoptosis measurement 
To examine apoptotic signalling in HCT116 p53-WT and p53-null cells after AAI exposure, the 
activities of two key effector enzymes that are involved in apoptosis in mammalian cells, caspase-3 
and -7, were measured by luminescence detection. While there was no difference in caspase activity 
observed in p53-null cells, increased activity was found in p53-WT cells after 24 and 48 h at 100 
µM AAI (Figure 6). Using a linear model with caspase activity being the response variable and 
explanatory variables TP53 status (categorical) and time (continuous) we found a statistically 
significant increase in caspase activity with time in p53-WT cells (P<0.0001). The time-dependent 
response was significantly different in p53-WT and p53-null cells (P<0.0001). This is consistent 
with the cell viability and DNA adduct data where the greatest loss of viability and DNA adduct 
formation only occurred in p53-WT cells. 3-NBA (5 µM), used as positive control, strongly induced 
caspase activity in a time-dependent manner, independent of the TP53 status (Figure 6). The latter 
observation is consistent with the finding that 3-NBA induces equally high levels of DNA adducts 
in both HCT116 p53-WT and p53-null cells (Hockley et al., 2008). 
 
Flow cytometry 
The identification of altered expression of transcripts that may affect cell cycle regulation and genes 
whose expression is tightly coupled with DNA metabolism, prompted the investigation of the 
effects of AAI on the cell cycle parameters in HCT116 p53-WT and p53-null cells. The DNA 
content of cells exposed to 0 or 100 µM AAI for up to 48 h was measured by FACS analysis 
(Figure 7). There was a clear accumulation of both cell types in the S phase after 24 and 48 h 
exposure to AAI when compared to controls (P<0.0001; Welch’s two-sample t-test using Benjamin 
Hocberg multiple testing correction). Arrest in the S phase implies that DNA synthesis is being 
inhibited in both cell types in response to AAI exposure. The fold increase in cells in S phase was 
similar in both cell lines indicating that the alterations of the cell cycle parameters do not depend on 
TP53 (P=0.274; ANOVA). 
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Induction of DNA strand breaks and oxidative DNA base modifications 
To assess the induction of DNA strand breaks and oxidative DNA base modifications by AAI, 
HCT116 cells were exposed to 0 or 100 µM AAI for up to 48 h and lesion frequencies were 
quantified by the alkaline unwinding technique in combination with the bacterial Fpg (Hartwig et 
al., 1996). Fpg recognises 7,8-dihydro-8-oxoguanine (8-oxoguanine), 2,6-diamino-4-hydroxy-5-
formamindopyrimidine (Fapy-Gua), 4,6-diamino-5-formamido-pyrimidine (Fapy-Ade) and to a 
smaller extent 7,8-dihydro-8-oxoadenine (8-oxoadenine) as well as apurinic/apyrimidinic sites (AP 
sites) and converts them into DNA strand breaks by its associated DNA endonuclease activity 
(Tchou et al., 1991; Boiteux et al., 1992). In untreated p53-WT and p53-null cells similar amounts 
of double stranded DNA in the absence and presence of Fpg were measured, demonstrating 
comparable background levels of DNA strand breaks and Fpg-sensitive sites. Overall, as shown in 
Figure 8, for all incubation times we observed only low level of DNA strand breaks, up to 0.2 
lesions/106 base pairs in both p53-WT and p53-null cells. A 5-min incubation of both pairs of cells 
with 100 µM hydrogen peroxide on ice (to omit DNA repair) as a positive control induced similar 
levels of DNA strand breaks and Fpg-sensitive sites, being up to 10-fold higher compared with cells 
treated with AAI (Figure 8). Although only low levels of DNA strand breaks were detected 
following exposure to AAI for 48 h, around twice as many DNA strand breaks were found in p53-
WT relative to p53-null cells. Similarly, only low levels of Fpg-sensitive sites were observed in 
both p53-WT and p53-null cells (Figure 8). Despite these low levels, after 48 h exposure to AAI 
around 2-times more Fpg-sensitive sites were detected in p53-null relative to p53-WT cells. It is 
noteworthy that TP53 has been assumed to be the major regulator of the expression and activity of 
the human 8-oxoguanine-DNA glycosylase (hOgg1) (Chatterjee et al., 2006), suggesting that in 
p53-null cells Fpg-sensitive sites are repaired much more slowly due to reduced expression levels of 
Ogg1, resulting in the higher accumulation of Fpg-sensitive sites in p53-null relative to p53-WT 
cells. 
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Discussion 
 
TP53 plays a key role in cellular response to genotoxic stress and is involved in several critical 
pathways including cell-cycle arrest, apoptosis, DNA repair and cellular senescence, which are 
essential to maintain genome integrity (Hussain et al., 2000). The importance of this protein is 
highlighted by the fact that it is mutated in 50% of human tumours (Petitjean et al., 2007). Using 
microarray technology AA-characteristic gene expression profiles were observed recently in rodents 
receiving short-term treatment with AA providing novel information on molecular mechanisms 
underlying AA-induced carcinogenesis (Chen et al., 2006; Stemmer et al., 2007). To investigate the 
role of TP53 in the cellular response to AA we compared the transcriptional and translational 
responses to AAI in human cells that differ in TP53 status. While no urothelial cell lines with 
disrupted TP53 were available, colorectal HCT116 cells with wild-type (p53-WT) or homozygously 
disrupted TP53 (p53-null) (Bunz et al., 1998) have been proven to be a valuable tool to examine 
gene expression profiles associated with the TP53 network in response to cellular stress and 
environmental carcinogens (Staib et al., 2005; Hockley et al., 2008). Moreover, in various 
genotoxicity studies HCT116 cells were found to metabolically activate a variety of different 
genotoxic agents (McDermott et al., 2005; Arlt et al., 2007a; Dornetshuber et al., 2007; Hockley et 
al., 2008). Among the compounds activated were nitro polycyclic aromatic hydrocarbons, 
demonstrating that these cells can catalyse bioactivation by nitroreduction (Arlt et al., 2007a), 
which is the major activation pathway for AA (Arlt et al., 2002; Stiborova et al., 2005; Stiborova et 
al., 2008).  
 AAN urothelial atypia have been associated with the overexpression of TP53 (Cosyns et al., 
1999), indicating its cellular accumulation in response to AA-induced DNA damage. Mutated TP53 
is often over-expressed in tumour cells and increasing evidence suggests that mutant TP53 is not 
only responsible for the loss of the tumour-suppressive functions but may also result in additional 
pro-oncogenic properties (Vikhanskaya et al., 2007). In the present study we found TP53 
accumulation in HCT116 p53-WT cells after AAI exposure. Interestingly, DNA adduct analysis 
revealed that adduct levels were ~40-fold higher in p53-WT cells at a dose (100 µM) and time point 
(48 h) where AA-DNA adducts were detected in both cell lines. DNA adduct levels induced by AAI 
in p53-WT cells was comparable to those observed in human breast carcinoma MCF-7 cells 
exposed to similar concentrations of AAI (10-100 µM) (Arlt et al., 2001b). AAI-DNA adducts have 
been linked with specific AT→TA transversion mutations in codon 61 of the H-ras gene leading to 
activation of this oncogene in AAI-induced tumours in rodents (Schmeiser et al., 1990; Arlt et al., 
2000). The same type of mutation was found in TP53 in urothelial tumour cells of an AAN patient 
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(Lord et al., 2004), suggesting that TP53 is mutated in AAN-associated tumours (Arlt et al., 2001b; 
Arlt et al., 2007b). Furthermore, AT→TA transversions were found in TP53 of immortalised cells 
derived from murine primary human TP53 knock-in (Hupki) embryonic fibroblasts exposed to AAI 
(Liu et al., 2004; Feldmeyer et al., 2006; vom Brocke et al., 2006). Interestingly, in one cell line the 
mutation was in codon 139, identical to one found in the urothelial tumour cells of the AAN patient 
(Lord et al., 2004; Feldmeyer et al., 2006). Moreover, a high frequency of AT→TA transversion 
mutations was found in the TP53 of urothelial tumours from patients with Balkan endemic 
nephropathy and exposed to AA (Grollman et al., 2007). These data indicate that TP53 plays an 
important role in the molecular mechanism whereby AA causes urothelial cancer (Arlt et al., 
2007b). In HCT116 cells exposed to benzo(a)pyrene (BaP) DNA adduct formation was also 
dependent on TP53, being significantly lower in p53-null than in p53-WT cells (Hockley et al., 
2008), suggesting that basal levels of TP53 are linked to the metabolic activation of both BaP and 
AAI. In contrast, no influence of TP53 on DNA adduct formation was seen after treatment of p53-
WT and p53-null cells with the diol-epoxide of BaP (BPDE) or with 3-NBA (Hockley et al., 2008). 
As the mechanism for the influence of TP53 on xenobiotic metabolism is not yet understood, the 
TP53-dependent effect on AA-DNA adduct formation requires further investigation. 
 Using cDNA microrray and RTqPCR we found only subtle changes in gene expression in 
p53-WT and p53-null cells after exposure to AAI and transcriptional responses were only evident at 
higher concentrations and after a longer duration of exposure. This was reflected in cell viability 
and may be due to the levels of DNA damage not being high enough to elicit a greater response. A 
small sub-set of gene expression changes were identified as discriminating TP53 status in AAI-
treated HCT116 cells but the TP53 status of the cells was only apparently critical after a longer 
exposure time of 24 h and at the highest concentration tested (100 µM). This may be the result of 
downstream gene expression alterations, dependent on TP53 activation, coming into effect over 
time. Similarly, BPDE induced a small number of TP53-dependent gene expression changes in 
these cells, although the number of TP53-regulated genes was greater than in the present study 
(Hockley et al., 2008). In Eker and WT rats treated with 10 mg/kg bw of AA (41% AAI, 56% 
AAII) for up to 14 days the TP53-regulated genes CDKN1A and CCNG1 were changed (up-
regulated) in a time-dependent manner (Stemmer et al., 2007). We found that CDKN1A and 
CCNG1 were changed in HCT116 cells exposed to AAI and these genes were identified as 
discriminating TP53 status in TK6 cells after DNA-damaging treatments (Amundson et al., 2005). 
CDKN1A encodes a potent cell cycle inhibitor, regulating cell cycle progression at the G1 and G2 
check-points in response to a variety of stress stimuli (el-Deiry et al., 1994; Ohtsuka et al., 2004), 
and was strongly up-regulated in p53-WT cells after AAI exposure (see below). Genes identified as 
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discriminating TP53 status in HCT116 cells after AAI exposure included CCNG1, EGR1, CAV1, 
NR1D1, and LCN2. CCNG1 encodes cyclin G1, which has growth inhibitory activity (Ohtsuka et 
al., 2004) and was strongly down-regulated in AAI-treated p53-null cells. It has been suggested that 
cyclin G-mediated TP53 regulation is dependent upon the status of ataxia-telangiectasia mutated 
(ATM) protein, which activates TP53 in response to DNA damage (Ohtsuka et al., 2004). The 
transcription factor early growth response 1 (EGR1) gene, which was one of the most highly up-
regulated genes in p53-WT cells, is a direct regulator of multiple tumour suppressors including 
TGFβ1, PTEN, TP53 and fibronectin (Krones-Herzig et al., 2005; Baron et al., 2006). EGR1 has 
important tumour suppressor properties, e.g. via the direct induction of the epithelial cell suppressor 
TGFβ1 and the direct induction of TP53 to promote apoptosis. CAV1 encodes for caveolin-1 that 
has been linked with oncogenic transformation, cancer and metastasis (Carver and Schnitzer, 2003; 
Williams and Lisanti, 2005) and was down-regulated in p53-null cells along with CAV2. NR1D1 
encodes for the orphan nuclear receptor Rev-Erbα, which is the major regulator of cyclic Bmal1 
transcription as part of the mammalian circadian rhythm (Preitner et al., 2002). Besides NR1D1, 
NR1D2 was also up-regulated both in p53-WT and p53-null cells. It is thought that disruption of the 
circadian rhythm may increase cancer risk (Gauger and Sancar, 2005). LCN2, which encodes for 
lipocalin 2, plays a role in cell regulation and penetration of lipophilic ligands through the cell 
membrane after lipocalin-mediated transport to the cell surface and interaction with cytosolic and/or 
nuclear proteins (see below) (Bratt, 2000; Hvidberg et al., 2005). Lipocalins have been linked with 
cancer development (Bratt, 2000). Although the list of TP53-dependent identified signature genes is 
small, this observation is consistent with other studies (Park et al., 2002; Amundson et al., 2005; 
Hockley et al., 2008). Therefore, the present study also shows that expression profiles induced by 
AAI are largely TP53-independent in HCT116 cells. However, we found AAI-induced apoptosis in 
HCT116 p53-WT cells but not in p53-null cells, indicating that apoptotic signalling, as measured by 
caspase activity, is TP53-dependent. 
 Tubular atrophy is a pathohistological feature in AAN (Cosyns, 2003) and AA-induced 
apoptosis in tubular cells may be responsible for it (Pozdzik et al., 2008). Indeed, apoptotic cells 
were detected in vivo within renal tubules of AA-treated rodents (Okada et al., 2003; Pozdzik et al., 
2008). Others have demonstrated that AA induces apoptosis in vitro in renal tubular cells 
(Balachandran et al., 2005; Hsin et al., 2006; Li et al., 2006; Qi et al., 2007). In porcine proximale 
tubular epithelial LLC-PK1 cells AA-induced apoptosis was associated with an increase in 
intracellular calcium concentration (Li et al., 2006). In canine renal distal tubular MDCK and 
human tubular epithelial HK-2 cells AA/AAI had an impact on the Ca2+ homeostasis by activating 
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Ca2+-release channels and/or inhibiting Ca2+-ATPases, causing both endoplasmic reticulum and 
mitochondria stress (Hsin et al., 2006; Qi et al., 2007). Interestingly, INSIG1 was down-regulated in 
HCT116 p53-WT cells after AAI exposure, INSIG1 being a protein closely related to endoplasmic 
reticulum proteins inducing cellular stress through its depletion (Lee and Ye, 2004). Moreover, 
CAPNS1 was down-regulated in both HCT116 p53-WT and p53-null cells after AAI exposure. 
Calpains are a family of Ca2+-dependent neutral cysteine proteases involved in a number of cellular 
events including apoptosis (Del Bello et al., 2007; Pineiro et al., 2007). Although the role of 
calpains in apoptosis is still poorly understood, results show a promoting or a protective role 
depending on the cell type studied, depending particularly on the concomitant involvement of the 
caspase machinery (Neumar et al., 2003). It is possible that the impact of AA exposure on the 
intracellular Ca2+ concentration (Hsin et al., 2006; Qi et al., 2007) may be linked to a modulation of 
calpain activity, and that calpain subsequently produces proteolysis of caspase-3 (as measured in the 
present study), thereby triggering apoptosis. Indeed caspase-3 and -7 activity was also increased in 
LLC-PK1 and HK-2 cells treated with AAI (Balachandran et al., 2005; Qi et al., 2007). Calpain 
acts upstream of TP53, and it was shown that calpain inhibition up-regulates TP53 levels and 
induces apoptosis in human tumour cell lines (Atencio et al., 2000). This could explain the TP53-
dependence of apoptosis in HCT116 cells as it only occurred in p53-WT cells. However, the role of 
calpains in AA-induced apoptosis requires further investigation. 
 A number of DNA-damaging agents have been shown to activate TP53 and inhibit cell 
growth by arrest at the G1/S boundary of the cell cycle (Dipple et al., 1999; Khan et al., 1999). This 
cell cycle arrest is thought to be an important cellular defence mechanism that prevents replication 
of damaged DNA. This arrest in G1 phase is mediated by TP53, which is stabilized as a result of 
DNA damage (el-Deiry et al., 1994). We found that exposure to AAI caused an accumulation of 
both p53-WT and p53-null cells in S phase. We showed that AAI selectively slows down the 
progression of HCT116 cells through S phase. Transcriptional activation of histone genes has been 
found in cells at the G1/S transition and during S phase (Stein et al., 2006). In the present study we 
observed up-regulation of HIST1H1C, HIST1H2AC, HIST1H3D, HIST1H3E, HIST1H4B and 
HIST1H4C in HCT116 cells exposed to AAI, indicating a transcriptional activation of these genes 
in response to accumulation of cells in S phase. It is tempting to speculate that the mechanism of the 
S phase delay is the inability of the DNA polymerase complex to replicate over AAI-induced DNA 
adducts. It has been shown that DNA damage blocks DNA replication and/or transcription by 
polymerase (Roos and Kaina, 2006). Indeed this has been observed in AA-modified DNA templates, 
demonstrating that AA-DNA adducts can efficiently block DNA polymerase (Broschard et al., 
1994; Arlt et al., 2000; Arlt et al., 2001b). Inhibition of DNA replication has also been implicated 
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as a proximate initiator of apoptosis (Roos and Kaina, 2006), which we found in p53-WT cells (see 
above). However, since AAI-mediated S phase arrest was seen in both p53-WT and p53-null cells, 
this indicates that its mechanism is TP53-independent. The concept of a stealth property of cells to 
evade a protective G1 arrest after DNA damage has been described for other potent carcinogens (e.g. 
polycyclic aromatic hydrocarbons and aflatoxin) (Khan et al., 1997; Khan and Dipple, 2000; 
Ricordy et al., 2002). Similarly, treatment of HCT116 p53-WT and p53-null cells with BPDE 
resulted in accumulation of cells in S phase and was independent of the cells’ TP53 status (Hockley 
et al., 2008), which is consistent with our findings. It has been suggested that lack of G1 arrest is 
through the inability of cells to induce the expression of the potent G1/G2 cell cycle inhibitor, 
CDKN1A (Khan et al., 1997). In this study, we saw accumulation of CDKN1A in p53-WT cells 
after AAI exposure for 48 h, but not for 24 h, a time-point at which S-phase accumulation already 
occurred. Similarly, only at the latest time-point (48 h) was TP53 accumulation observed in p53-
WT cells. In HCT116 p53-WT cells exposed to BPDE, accumulation of CDKN1A was found at 
time-points at which accumulation of cells in S phase was observed, but no G1 arrest occurred 
(Hockley et al., 2008). In contrast, a dose-dependent G1 arrest was found in human urinary tract 
epithelium SV-HUC-1 cells following treatment with AA (41% AAI, 56% AAII) at a similar 
concentration to that used in our study (100 µM) (Chang et al., 2007). Consistent with this 
functional outcome, levels of TP53 and CDKN1A were increased in AA-treated SV-HUC-1 cells. 
Moreover a decrease in the activity of cyclin E/cdk2 complex was induced by the increase of TP53 
and CDKN1A, resulting in pRB hypophosphorylation, preventing AA-treated SV-HUC-1 cells 
undergoing transition to S phase (Chang et al., 2007). Although TP53 and CDKN1A accumulation 
(at 24 h) and cell cycle parameters (at 48 h) in SV-HUC-1 cells have been measured only at 
different time-points (Chang et al., 2007), the strong induction of TP53 and CDKN1A seen after 24 
h may suggest that higher initial DNA damage (AA-DNA adduct level) is probably responsible for 
the observed G1 arrest after 48 h. Besides cell-type specific effects, it is tempting to speculate that 
the lower AAI-induced DNA adduct levels in HCT116 p53-WT and p53-null cells after 24 h 
account for a difference in the rate of TP53 accumulation and induction of CDKN1A. Subsequently, 
levels of the latter proteins were not high enough to trigger G1 arrest. Consequently, replication of 
AA-damaged DNA may result in mutation leading to malignant transformation of the AA-exposed 
cells (Khan and Dipple, 2000). 
 Previous studies have indicated that a subset of urothelial cancers might have a strong 
predisposition to gene amplification, and that crucial genetic alterations other than TP53 mutations 
might be responsible for this predisposition (Schulz, 2006). For example, MYC overexpression has 
been found frequently in advanced urothelial carcinomas (Habuchi et al., 1994; Grimm et al., 1995; 
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Schulz et al., 1998), and this may also have some relevance in AAN-associated urothelial 
carcinomas, although this has not yet been investigated in clinical samples. Interestingly, we found 
up-regulation of MYC in HCT116 cells after AAI exposure, although this was not clearly apparent 
at the protein level. MYC is required in normal cells for cell cycle competence, whereas in tumour 
cells it is over-expressed and functions as the angiogenic switch (Nilsson and Cleveland, 2003). 
Other oncogenes with altered expression in AAI-treated HCT116 cells included FOS (down-
regulated) and ROHB (up-regulated), both genes linked to progression of human cancers (Kamai et 
al., 2003; Wheeler and Ridley, 2004; Milde-Langosch, 2005). RAS is another oncogene that has 
been shown to be activated (mutated) in AA-induced tumours (Schmeiser et al., 1990). Thus, in 
addition to TP53, disruption of oncogenic pathways of e.g. MYC, RAS, FOS and/or ROHB may be 
involved in the development and progression of AA-induced urothelial tumours, and may be 
valuable prognostic markers in future clinical studies. 
 One of the earliest clinical signs of AAN is urinary excretion of low-molecular-weight 
proteins, indicating that AA is toxic to proximal tubule cells (Kabanda et al., 1995). Indeed, 
previous studies have shown that AA inhibits receptor-mediated endocytosis of low-molecular-
weight proteins in proximal tubule cells, which is associated with decreased megalin expression 
(Lebeau et al., 2001; Lebeau et al., 2005). It is noteworthy that the endocytotic receptor megalin 
binds the transporting neutrophil-gelatinase-associated lipocalin (LCN2) with high affinity and 
mediates its cellular uptake (Hvidberg et al., 2005). LCN2 was selectively down-regulated in 
HCT116 p53-WT cells after AAI exposure. In opossum kidney cells a causal relationship between 
AA-DNA adduct formation and the inhibition of receptor-mediated endocytosis was found, 
suggesting that AA-DNA adducts might impair such physiological processes (Lebeau et al., 2001). 
Interestingly, we found two genes linked to endocytosis in HCT116 cells exposed to AAI, namely 
NECAP1 (down-regulated) and RAB5A (up-regulated). NECAP1 has been shown to play a role in 
clathrin-mediated endocytosis, although its precise function is unclear (Ritter et al., 2003). A 
function of RAB5A is to regulate endosome fusion, but a key role for this small GTPase in the 
initial phases of receptor-mediated endocytosis is also emerging (Lanzetti et al., 2001; Christensen 
et al., 2003). Thus, changes in NECAP1 and RAB5A expression may play a role in AA-induced 
inhibition of receptor-mediated endocytosis. 
 
Conclusions 
Phenotypic anchoring of the AAI-induced expression profiles to DNA adduct formation, cell cycle 
parameters, TP53 protein expression and apoptosis identified a number of genes that are linked to 
these biological outcomes. Some of them are TP53-dependent, thereby indicating them as target 
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genes in the development of AA-induced carcinogenesis. Although these results strengthen the 
important role of TP53 in AA-induced cancer, crucial genetic alterations other than TP53 mutations 
(e.g. disruption of oncogenic pathways such as MYC) may also contribute to tumour development. 
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Table 1 
Genes with expression significantly different (P<0.05; 1-Way ANOVA) between HCT116 p53-WT and p53-null cells after exposure to 100 µM 
AAI for 24 and 48 hours 
    24 h 48 h 
Image Clone IDa Gene symbol Genbank ID Description p53-WT p53-null p53-WT p53-null 
207288 INSIG1 NM_198336 Insulin induced gene 1 0.79 0.89 0.58 0.94 
358457 HNRPH1 BX647205 Heterogeneous nuclear ribonucleoprotein H1 (H) 1.20 1.04 1.60 1.10 
810504 PLP2 BF214130 Proteolipid protein 2 (colonic epithelium-enriched) 0.66 0.78 0.63 0.71 
840944 EGR1 NM_001964 Early growth response 1 3.14 2.33 3.25 2.02 
269745 DCBLD2 NM_080927 Discoidin, CUB and LCCL domain containing 2 0.91 0.80 0.86 0.64 
32134 DNAJC9 AK094162 DnaJ (Hsp40) homolog, subfamily C, member 9 0.69 0.82 0.73 0.83 
377461 CAV1 NM_001753 Caveolin 1, caveolae protein, 22kDa 0.86 0.80 0.93 0.70 
795330 NR1D1 M24898 Nuclear receptor subfamily 1, group D, member 1 1.31 1.87 1.84 2.58 
741497 LCN2 BU174414 Lipocalin 2 (oncogene 24p3) 0.65 0.94 0.54 0.94 
32834 SQLE BX647605 Squalene epoxidase 0.62 0.87 0.70 0.82 
200862 CAV1 NM_001753 Caveolin 1, caveolae protein, 22kDa 0.87 0.73 0.88 0.66 
269119 CAV1 NM_001753 Caveolin 1, caveolae protein, 22kDa 0.83 0.70 0.84 0.70 
814798 ALDH1A3 AF198444 Aldehyde dehydrogenase 1 family, member A3 1.56 1.15 1.59 0.97 
205819 CPM NM_001874 Carboxypeptidase M 1.32 1.01 1.83 0.97 
1711438 MIF BQ056329 Macrophage migration inhibitory factor (glycosylation-inhibiting factor) 1.07 0.76 0.95 0.70 
35516 CCNG1 NM_004060 Cyclin G1 0.88 0.70 0.87 0.61 
253009 MALAT1 BX538238 Metastasis associated lung adenocarcinoma transcript 1 (non-coding RNA) 0.62 1.01 0.68 0.95 
41979 FLJ14525 BC066649 Hypothetical protein FLJ14525 0.65 0.94 0.63 0.85 
a
 Image clone 150085 has been significantly (P<0.05) modulated but no gene symbol and/or Genbank ID was identified. 
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Table 2 
Biological processes significantly over-represented (EASE Score<0.05) within the gene expression profiles induced after exposure to 100 µM 
AAI for 24 and 48 hours in HCT116 p53-WT and p53-null cells  
Biological Process p53-WT p53-null 
RNA splicing; RNA processing; RNA metabolism PPP2CA; RNPC2; SF3A1; SFPQ; SFRS1; SFRS10; SFRS3; SFRS7; CSTF3; 
HNRPH1 ↑a 
CSTF3; HNRPDL; RNPC2; SF3A1; SFPQ; SFRS1; SFRS10; SFRS7; YARS ↑ 
mRNA splicing; mRNA processing; mRNA 
metabolism 
CSTF3; RNPC2; SF3A1; SFPQ; SFRS1; SFRS10; SFRS3; SFRS7 ↑ CSTF3; RNPC2; SF3A1; SFPQ; SFRS1; SFRS10; SFRS7 ↑ 
metabolism AGA; ALDH1A3; ATF3; CHD2; CPM; CSE1L; CSTF3; EGR1; IF2S1;EIF2S2; 
FHL2; FLJ10378; FLJ11021; GOT1; HIST1H2AC; HNRPH1; NFKBIA; 
NR1D1; NR1D2; ODC1; PIP5K1A; PPP2CA; PPP2R2A; PTP4A1; RNPC2; 
SF3A1; SFPQ; SFRS1; SFRS10; SFRS3; SFRS7;TCERG1; TOMM34; 
UBE2V2; XRCC4; ZYX ↑ 
ARSF; ATF3; CHD2; CSTF3; EGR1; FLJ10378; FLJ11021; GOT1; HIST1H1C; 
HIST1H2AC; HIST1H3D; HNRPDL; MYC; NR1D1; NR1D2; NTRK2; ODC1; 
PPP2R2A; PTP4A1; RNPC2; RPA2; SF3A1; SFPQ; SFRS1; SFRS10; SFRS7; 
SLC3A2; TOMM34; YARS ↑ 
nucleobase, nucleoside, nucleotide and nucleic 
acid metabolism 
ATF3; CHD2; CSTF3; EGR1; FHL2; FLJ11021; HIST1H2AC;  HNRPH1; 
NR1D1; NR1D2; PPP2CA; RNPC2; SF3A1; SFPQ; SFRS1; SFRS10; SFRS3; 
SFRS7; TCERG1; UBE2V2; XRCC4 ↑ 
ATF3; CHD2; CSTF3; EGR1; FLJ11021; HIST1H1C; HIST1H2AC; HIST1H3D; 
HNRPDL; MYC; NR1D1; NR1D2; RNPC2; RPA2; SF3A1; SFPQ; SFRS1; 
SFRS10; SFRS7; YARS ↑ 
chromatin assembly/disassembly CHD2; FLJ11021; HIST1H2AC ↑ CHD2; FLJ11021; HIST1H1C; HIST1H2AC; HIST1H3D ↑ 
nucleosome assembly 
−
b
 FLJ11021; HIST1H1C; HIST1H2AC; HIST1H3D ↑ 
chromatin architecture; chromosome organization  
− CHD2; FLJ11021; HIST1H1C; HIST1H2AC; HIST1H3D ↑ 
DNA packaging 
− CHD2; FLJ11021; HIST1H1C; HIST1H2AC; HIST1H3D ↑ 
physiological process 
− 
AP3S1; ARSF; ATF3; CHD2; CSTF3; EGR1; FLJ10378; FLJ11021; GOT1; 
HIST1H1C; HIST1H2AC; HIST1H3D; HNRPDL; MT1F; MYC; NR1D1; NR1D2; 
NTRK2; ODC1; PPP2R2A; PTP4A1; RNPC2; RPA2; SF3A1; SFPQ; SFRS1; 
SFRS10; SFRS7; SLC3A2; TOMM34; YARS ↑ 
DNA metabolism 
− CHD2; FLJ11021; HIST1H1C; HIST1H2AC; HIST1H3D; RPA2 ↑ 
   
protein biosynthesis 
− 
DDOST; IARS; RPL10; RPL12; RPL21; RPL27A; RPL31; RPL37A; RPS16; RPS9 
↓ a 
macromolecule biosynthesis 
− 
DDOST; FDFT1; IARS; RPL10; RPL12; RPL21; RPL27A; RPL31; RPL37A; 
RPS16; RPS9; SCD ↓ 
biosynthesis 
− 
DDOST; FDFT1; IARS; RPL10; RPL12; RPL21; RPL27A; RPL31; RPL37A; 
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RPS16; RPS9; SCD ↓ 
ribosome biogenesis and assembly 
− RPL12; RPL21; RPS16 ↓ 
protein folding 
− DNAJB11; HSPA8; PPIB; TRA1 ↓ 
protein metabolism 
− 
DDOST; DNAJB11; HSPA8; IARS; PLAT; PPIB; RPL10; RPL12; RPL21; 
RPL27A; RPL31; RPL37A; RPS16; RPS9; TRA1; UBE2M ↓ 
secretion 
− CANX; ERP70; SYN2 ↓ 
a
 ↑ up-regulated expression; ↓ down-regulated expression. 
b
−, no over-represented gene expression alterations were found. 
 33
Table 3 
Differential expression of selected genes in HCT116 p53-WT and p53-null cells after exposure 
to 100 µM AAI for 48 h 
 p53-WT p53-null 
 
 
Gene 
RT-PCRa 
[fold-
change] 
 
RT-PCR 
[direction] 
 
Microarray 
[direction] 
RT-PCR 
[fold-
change] 
 
RT-PCR 
[direction] 
 
Microarray 
[direction] 
ALDH1A3 3.0 ↑ ↑ 1.0 − − 
CCNG1 1.8 ↑ − 0.2 ↓ ↓ 
HIST1H4B 5.3 ↑ ↑ 1.3 − ↑ 
SCD 0.1 ↓ ↓ 0.2 ↓ ↓ 
MYC 6.4 ↑ − 2.6 ↑ ↑ 
FOS 0.1 ↓ ↓ 0.1 ↓ ↓ 
ROHB 2.2 ↑ − 2.7 ↑ ↑ 
NR1D1 63.8 ↑ ↑ 22.3 ↑ ↑ 
CAV1 0.99 
− − 
0.5 ↓ ↓ 
CDKN1A 18.6 ↑ ↑ 1.3 − − 
CYP1A1 6.6 ↑ ⊗ 2.4 ↑ ⊗ 
a
 All results represent mean of three incubations; each sample was determined by three separate 
analyses. ↑ = up-regulated; ↓ = down-regulated; − = unaltered expression; ⊗ = gene not present on 
microarray. 
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Legend to Figures: 
 
Figure 1 
Effect of AAI on viability (% control) of (A) HCT116 p53-WT and (B) HCT116 p53-null cells. 
Values represent means of two independent experiments.  
 
Figure 2 
Quantitative 32P-postlabelling analysis of total AA-DNA adducts in (A) HCT116 p53-WT and (B) 
HCT116 p53-null cells. Insets: autoradiographic profile of AA-DNA adducts obtained in (A) 
HCT116 p53-WT and (B) HCT116 p53-null cells after exposure to 100 µM AAI for 48 h. The 
origin, in the bottom left-hand corner, was cut off before exposure. Spot 1, dA-AAI; spot 2, dG-
AAI; spot 3, dA-AAII. 3-NBA (5 µM) was used as a positive control (Hockley et al., 2008). 
 
Figure 3 
Venn diagram illustrating the overlap of gene expression profiles of HCT116 p53-WT and HCT116 
p53-null cells induced by AAI exposure altered by at least 1.4-fold (P<0.05). Gene expression 
changes after exposure to (A) 50 or 100 µM AAI for 6, 24 or 48 h and (B) 100 µM AAI for 24 or 
48 h. 
 
Figure 4 
Gene expression analysis of HCT116 cells exposed to AAI. (A) Hierarchical clustering and (B) 
Principal component analysis of genes modulated in at least one of the cell lines after AAI exposure 
to 50 or 100 µM AAI for 6, 24 or 48 h (210 genes). 
 
Figure 5 
Western blot analysis of (A) TP53 and (B) CDKN1A protein expression in HCT116 cells exposed 
to AAI. GAPDH antibody was used to detect GAPDH protein expression, which was used as 
loading control.  
 
Figure 6 
Apoptosis assay in (A) HCT116 p53-WT and (B) HCT116 p53-null exposed to 100 µM AAI. The 
activities of caspase-3 and caspase-7 were measured by luminescence detection. The values are the 
mean ± SD (n=6). 3-NBA (5 µM) was used as a positive control. 
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Figure 7 
Cell cycle parameters in (A) HCT116 p53-WT and (B) HCT116 p53-null exposed to 100 µM AAI. 
The values are the mean ± SD of six determinations (triplicate analyses of two separate cell 
incubations).  
 
Figure 8 
Induction of DNA strand breaks and oxidative DNA base modifications in (A) HCT116 p53-WT 
and (B) HCT116 p53-null exposed to 100 µM AAI. The frequencies of DNA strand breaks and 
Fpg-sensitive sites were determined by alkaline unwinding as described in the Material and 
Methods. The values are the mean ± SD of six determinations (triplicate analyses of two separate 
cell incubations). Shown are induced lesions; background levels of Fpg-sensitive sites in untreated 
p53-WT and p53-null cells were 0.035 ± 0.025 and 0.034 ± 0.021 per 106 base pairs, respectively. 
Hydrogen peroxide (H2O2; 100 µM; 5 min on ice) was used as a positive control. 
 
Figure 9 
Postulated mechanistic pathways of AA-induced toxicity (adapted and modified from (Stemmer et 
al., 2007)). Black, pathways and processes suggested from the literature; blue, pathways and 
processes implicated by gene expression analysis; green, pathways and processes determined by 
biological analysis and corroborated by gene expression analysis. ER, endoplasmic reticulum. ?, 
unknown pathway in response to AA exposure. 
  
 36
 
 
 
 
 
 
 
 
 
Figure 1 
  
AAI [µM]
v
ia
bl
e 
ce
lls
 
(%
 
co
n
tr
o
l)
A
6 h
24 h
48 h
6 h
24 h
48 h vi
a
bl
e 
ce
lls
 
(%
 
co
n
tr
o
l)
B
AAI [µM]
0 10 20 30 40 50 60 70 80 90 100
0
20
40
60
80
100
120
0 10 20 30 40 50 60 70 80 90 100
0
20
40
60
80
100
120
v
ia
bl
e 
ce
lls
 
(%
 
co
n
tr
o
l)
v
ia
bl
e 
ce
lls
 
(%
 
co
n
tr
o
l)
 37
 
 
 
 
 
 
 
 
Figure 2  
0
5
10
10
30
50
70
90
110
130
150
170
1
0
5
10
10
30
50
70
90
110
130
150
170
1
11
2 3
ND ND NDNDNDNDNDNDNDND
6 h 24 h 48 h6 h 24 h 48 h
D
N
A
 
a
dd
u
ct
s 
pe
r 
10
8
n
u
cl
eo
tid
es
D
N
A
 
a
dd
u
ct
s 
pe
r 
10
8
n
u
cl
eo
tid
es
A B
50 µM
AAI
100 µM
AAI
10 µM
AAI
5 µM
3-NBA
0
200
400
600
800
1000
1200
1400
1600
1 48 h24 h
0
200
400
600
800
1000
1200
1400
1600
124 h 48 h
50 µM
AAI
100 µM
AAI
10 µM
AAI
5 µM
3-NBA
D
N
A
 
a
dd
u
ct
s 
pe
r 
10
8
n
u
cl
eo
tid
es
D
N
A
 
a
dd
u
ct
s 
pe
r 
10
8
n
u
cl
eo
tid
es
 38
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3  
p53-WT
(118 genes)
p53-null
(123 genes)
(37 up,
19 down)
(40 up,
22 down)
(21 up,
46 down)
p53-WT
(133 genes)
p53-null
(138 genes)
(39 up,
22 down)
(43 up,
29 down)
(28 up,
49 down)
B
A
 39
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4  
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Figure 5 
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Figure 6  
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Figure 8 
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Figure 9 
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